Humanigen shares splinter on lenzilumab failure in COVID-19

14 July 2022

Californian cytokine storm specialist Humanigen (Nasdaq: HGEN) lost 80% of its market value on Wednesday based on the results of the National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B trial.

This study is evaluating Humanigen’s lenzilumab plus remdesivir, a drug marketed by Gilead Sciences (Nasdaq: GILD) as Veklury, versus placebo plus remdesivir in hospitalized COVID-19 patients.

"Not able to confirm the positive results we saw in our Phase III LIVE-AIR study"The trial failed to achieve statistical significance on the primary endpoint, which was measured by the number of patients aged under 85 years with baseline CRP who remained alive and did not need mechanical ventilation through day 29.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK